



Systematic Review PHILOS Synthesis for Proximal Humerus Fractures Has High Complications and Reintervention Rates: A Systematic Review and Meta-Analysis

Lorenzo Massimo Oldrini¹, Pietro Feltri^{1,*}, Jacopo Albanese¹, Francesco Marbach¹, Giuseppe Filardo^{1,2} and Christian Candrian^{1,2}

- ¹ Service of Orthopaedics and Traumatology, Department of Surgery, EOC, 6900 Lugano, Switzerland; lorenzomassimo.oldrini@eoc.ch (L.M.O.); jacopo.albanese@eoc.ch (J.A.); francesco.marbach@eoc.ch (F.M.); giuseppe.filardo@eoc.ch (G.F.); christian.candrian@eoc.ch (C.C.)
- ² Faculty of Biomedical Sciences, Università della Svizzera Italiana, Via Buffi 13, 6900 Lugano, Switzerland
- * Correspondence: pietro.feltri@eoc.ch

Abstract: Purpose: The aim of this study was to quantify the rate of complications and reinterventions in patients treated with PHILOS plate for proximal humerus fractures (PHFs) synthesis. Methods: A comprehensive literature search was performed on the PubMed, Web of Science, Embase, and Cochrane databases up to 7 October 2021. Studies describing medium and long-term complications in PHF synthesis using the PHILOS plate were included. A systematic review and meta-analysis were performed on complications and causes of reinterventions. Assessment of risk of bias and quality of evidence was performed with the Downs and Black's "Checklist for Measuring Quality". Results: Seventy-six studies including 4200 patients met the inclusion criteria. The complication rate was 23.8%, and the main cause was screw cut-out (4.1%), followed by avascular necrosis (AVN) (3.1%) and subacromial impingement (1.5%). In patients over 55 years, the complication rate was 29.5%. In the deltopectoral (DP) approach the complication rate was 23.8%, and in the delto-split (DS) it was 17.5%, but no difference between the two approaches was seen when considering the type of fracture. The overall reintervention rate was 10.5% in the overall population and 19.0% in older patients. Conclusions: Proximal humerus synthesis with a PHILOS plate has high complications and reintervention rates. The most frequent complication was screw cut-out, followed by humeral head AVN and subacromial impingement. These results need to be further investigated to better understand both the type of patient and fracture that is more at risk of complications and reintervention and to compare pros and cons of the PHILOS plate with respect to the other solutions to manage PHFs.

Keywords: PHILOS; locking plate; proximal humeral fracture; PHF; osteosynthesis

1. Introduction

Proximal humerus fractures (PHFs) represent 5% to 10% of all fractures, being the third most frequent in the elderly population after femur and wrist fractures [1], and these numbers are constantly increasing due to the aging of the population [2,3]. The most appropriate treatment should be chosen based on the patient's age, bone quality, co-morbidities, compliance, and functional demands. Patients are frequently treated non-operatively, but when surgical treatment is necessary, different techniques can be performed such as percutaneous pinning, plating, arthroplasty, or intramedullary nail [4–6]. Among the surgical treatments, open reduction and internal fixation (ORIF) is the most used, although it presents several downsides such as an increased risk of avascular necrosis (AVN) of the humeral head, non-union, malunion, and screw cut-out [7].

To overcome these problems and increase patient functional outcomes, an anatomical plate design was developed [6,8,9] by the AO/ASIF group: the Proximal Humeral Internal



Citation: Oldrini, L.M.; Feltri, P.; Albanese, J.; Marbach, F.; Filardo, G.; Candrian, C. PHILOS Synthesis for Proximal Humerus Fractures Has High Complications and Reintervention Rates: A Systematic Review and Meta-Analysis. *Life* **2022**, *12*, 311. https://doi.org/10.3390/ life12020311

Academic Editors: Claudia Neunaber, Milena Fini, Paolo Cinelli and Nicola Smania

Received: 20 December 2021 Accepted: 17 February 2022 Published: 19 February 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). Locking System (PHILOS) plate. The PHILOS plate is an internal fixation system that enables stabilization thanks to multiple angular stable interlocking screws, with the goal of preserving the biological integrity of the humeral head while securing an anatomical reduction [10]. This method of fixation allows early mobilization, and thanks to the presence of numerous holes in its proximal portion, it also allows if needed an anchorage for rotator cuff sutures. The indications for the use of the PHILOS plate are various: two-, three-, four-fragment dislocations of proximal humerus fracture including fractures in osteoporotic patients, pseudoarthrosis, and osteotomy in the proximal humerus [11]. The reliability of this device led the PHILOS plate to become the standard surgical treatment for the fixation of PHFs. Despite its large use, the focus has been largely placed on the functional results, while less attention has been paid to the rate and type of complications of this treatment approach [12].

The aim of this systematic review and meta-analysis was to quantify and critically analyze the rate of complications and reinterventions following surgical treatment with the PHILOS plate of PHFs.

2. Materials and Methods

2.1. Literature Search

A review protocol was developed based on the Preferred Reporting Items for Systematic Reviews (PRISMA) statement (www.prisma-statement.org, accessed on 1 October 2021). A comprehensive search of the literature was performed in the bibliographic databases PubMed, Web of Science, Embase, and Wiley Cochrane Library from inception up to 7 October 2021. The following research terms were used: ((proximal humer* OR shoulder OR humer*) AND (fractur*) AND (internal locking system OR PHILOS OR plate)). Comparative and non-comparative studies describing medium and long-term complications in PHF synthesis using the Synthes PHILOS[®] plate were included. Only articles with a follow-up of more than 12 months were considered. Case reports or case series describing \leq five cases and articles in languages other than English were excluded. Pre-clinical and ex vivo studies, long PHILOS, shaft fractures, pathologic fractures, fixation with augmentation, and review articles were also criteria for exclusion.

2.2. Data Extraction

Two independent reviewers (LMO and PF) screened all the titles and abstracts. After this first screening, the articles that met the inclusion criteria were screened for full-text eligibility and were excluded if they met one of the exclusion criteria. In case of disagreement between the two reviewers, a third reviewer (JA) was consulted. An electronic table for data extraction was created prior to the study using Excel (Microsoft). The following data were extracted: title, first author, year of publication, journal, type of study, population characteristics, follow-up, type of fracture, functional outcomes, surgical technique, complications, reinterventions, and plate removal reasons. Plate removal carried out at the patient's will without giving an explanation was not included in the complication count.

The Downs and Black's "Checklist for Measuring Quality" was used to evaluate the risk of bias [13]; it is easy to use and provides a numeric score out of a possible 32 points. It contains 27 'yes'-or-'no' questions across five sections. The five sections include questions about the overall quality of the study (10 items), the ability to generalize findings of the study (3 items), the study bias (7 items), the confounding and selection bias (6 items), and the power of the study (1 item). Assessment of risk of bias and quality of evidence was completed independently for all outcomes by two authors and a third author solved any possible discrepancy.

2.3. Statistical Analysis

The Mantel–Haenszel method was used to provide pooled rates across the studies. A statistical test for heterogeneity was first conducted with the Cochran Q statistic and I2 metric and was considered the presence of significant heterogeneity with I2 values $\geq 25\%$. When no heterogeneity was found with I2 < 25%, a fixed-effect model was used to estimate the pooled rates and 95% C.I.s. Otherwise, a random-effect model was applied, and an I2 metric was evaluated for the random effect to check the correction of heterogeneity. The study' rate confidence intervals were carried out using the continuity-corrected Wilson interval [14]. The statistical significance of the difference between groups was based on the z statistics. All statistical analysis was carried out with Microsoft Excel 2010.

3. Results

3.1. Details of the Included Studies

A total of 8482 articles were retrieved; after the removal of duplicates, screening on the titles, abstracts, and full-texts, 78 articles were included in the systematic review (Figure 1). A total of 4200 patients (65.6% females) with 4202 fractures were included; the mean age was 60.3 years, and the mean follow-up was 19.9 months. Seventy studies reported the fracture type: 992 were two-part, 1446 three-part, and 888 four-part according to the Neer classification [15]. Moreover, 13 articles (886 fractures) included only patients older than 55 years. The standard deltopectoral (DP) approach was used in 60 studies (2966 patients) and the delto-split (DS) approach was used in 16 studies (671 patients). Among these, seven studies (547 patients) used both approaches; in addition, nine studies (563 patients) did not report the approach used (Table 1 for further details).



Figure 1. P.R.I.S.M.A. (Preferred Reporting Items for Systematic Meta-Analyses) flowchart of the study selection process. Assessment of risk of bias and quality of evidence.

$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Eirst Author Voor	Country	Comparativo	D4 (M E)	٨٥٥	Neer	Classifie	cation	Mean	Surgical
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	First Autnor; Year	Country	Comparative	Pt. (M-F)	Age	N2	N3	N4	Follow-Up	Approach
	Acklin et al., 2009	Switzerland	NO	29 (9-20)	64	N/A	N/A	N/A	12	DS
Aggorval et al., 2010IndiaNO 4^{-} (Z2–20)58.511221517115151617171518161717151817121518171215181712131313131412161716181412121217181814131213141415151616161315161616141413121214171017161614141410121616161414141012161616161414141012121417161616141410121214171616161413111610171616161413111112131315161716161413141213131516171616161413141213151617161616131616171616161315161716161617161616121616<	Acklin et al., 2013	Switzerland	NO	97 (N/A)	62	N/A	N/A	N/A	18	DS
Basedelier et al., 2014 Cermany NO 50 (d) - 50 62.7 15 18 17 12 D5 Bendalovic et al., 2014 Switzerland YES 282 (85-197) 64 58 153 74 123 DPT/DS Bersere et al., 2017 Switzerland YES 282 (85-197) 64 58.8 141 71 42 23 DPT/DS Borner et al., 2016 Austria NO 57 (61-46) 64 18 4 10 51 DPT DP Boudatoric et al., 2014 France YES 28 (16-46) 64 18 4 10 51 DP DP Bet al., 2017 Switzerland YES 28 (16-42) 643 18 10 11 24 DP DP DP DB 641 124 10 11 12 24 DP DP DD 12 12 12 11 11 12 DP DD DD DE DD DD	Aggarwal et al., 2010	India Dakistan	NO NO	47(27-20)	58.5	11	22	14	21.5	DP
	Bachelier et al. 2016	Germany	NO	20(12-8) 50(20-30)	40 62 7	4 15	10	0 17	12	DF
	Bandalovic et al., 2014	Croatia	NO	67 (N/A)	N/A	N/A	N/A	N/A	14.7	DP/DS
Bhaynan et al., 2021 India YES 84 (45–39) 45 0 40 44 23 DP/DS biordentiant 12,214 67 33 22 12 12 12,5 DP biordentiant 12,017 Soritzerland YES 63 (19–14) 96,6 13 17 12,0 21,7 DP/DS Buchmann et al., 2021 China YES 43 (17–31) 66,3 28 13 7 15,6 DP Caliskance t12, 2021 China YES 14 (18–27) 53,8 11 21 13 25 DE Claut al., 2017 Korea YES 32 (12–27) 50,41 12 17 6 12 DP Chore at al., 2017 Korea YES 33 (13 22) 56,1 12 17 6 12 DP Davids et al., 2010 Brazil NO 25 (12–27) 59 14 23 35 11 12 DP Davids et	Beeres et al., 2017	Switzerland	YES	282 (85–197)	64	58	153	74	12.3	DP/DS
	Bhayana et al., 2021	India	YES	84(45-39)	45	0	40	44	23	DP/DS
$ \begin{array}{c} \begin{array}{c} \mbodesizes (12,2017) & \mbodesizes (12,2014) & \mbodesizes (12,2015) & \mbodesizes (12,2017) & \mbodesizes (12,2015) & \mbodesizes (12,2015) & \mbodesizes (12,2015) & \mbodesizes (12,2015) & \mbodesizes (12,2017) & \mbodesizes (12,2017) & \mbodesizes (12,2015) & \mbodesizes (12,2017) & \mbodesizes (12,2015) & \mbodesizes (12,2016) & \mbodesizes (12,2$	Bjorkenheim et al., 2004 Boosmuoller et al., 2016	Finland	NO	72(28-44) 154(61-93)	67 55.8	38 41	22	12	12	DP
Benediard et al., 2014 France. YES 33 (19-14) 49/6 0 21 12 24/7 DP But et al., 2021 Switzerland YES 48 (17-31) 64.3 N/A N/A N/A 12 DP DS Cal et al., 2012 Switzerland YES 12 (1-11) 21 11 21 13 25 DP Cha et al., 2019 China YES 23 (8-24) 67.8 8 21 3 15 DP Chen et al., 2019 China YES 112 (37-75) 64.29 52 60 0 15 DP Chon et al., 2020 Taiwan YES 35 (13-22) 59 14 22 3 45 DP Dashi et al., 2020 Bacal NO 39 (12-27) 59 14 22 3 45 DP Dashi et al., 2017 Monal NO 83 (24-29) 54.3 19 17 11 12 DP Dashi et al., 2019	Borer et al., 2017	Switzerland	YES	62(16-46)	64	18	4	10	51	DP/DS
	Boudard et al., 2014	France	YES	33 (19–14)	49.6	0	21	12	24.7	DP
Buchmann et al., 2021 Switzerland YES 198 (7-123) 64.3 N/A N/A 12 DP/D Catiskan et al., 2019 Fouth YES 43 (18-27) 53.2 11 21 13 25 DF Catiskan et al., 2019 Fouth YES 32 (8-24) 67.8 8 21 3 15 DP Chen et al., 2019 China YES 31 (3-27) 56.1 12 17 6 12 DP Choet al., 2020 South NO 39 (12-27) 59 14 22 3 45 DP Daski et al., 2020 USA YES 75 (N/A) 59.9 40 35 0 17.6 DP Daski et al., 2017 India NO 53 (24-29) 56.3 7 40 35 32 DP Fazzel et al., 2014 Haby NO 25 (27-57) 66.43 N/A N/A N/A N/A N/A N/A N/A N/A <td< td=""><td>Bu et al., 2021</td><td>China</td><td>YES</td><td>48 (17-31)</td><td>66.3</td><td>28</td><td>13</td><td>7</td><td>15.6</td><td>DP</td></td<>	Bu et al., 2021	China	YES	48 (17-31)	66.3	28	13	7	15.6	DP
	Buchmann et al., 2021	Switzerland	YES	198(75-123) 12(1 11)	64.3 72.4	N/A	N/A	N/A 12	12	DP/DS
	Caliskan et al., 2012	Turkey	YES	45(18-27)	53.2	11	21	12	24	DI
Chen et al., 2019Korea120 50 50 64.29 50 64 20 10 11 <t< td=""><td>Chaetal 2017</td><td>South</td><td>VES</td><td>32(8-24)</td><td>67.8</td><td>8</td><td>21</td><td>3</td><td>15</td><td>קר</td></t<>	Chaetal 2017	South	VES	32(8-24)	67.8	8	21	3	15	קר
$\begin{array}{c} \mbox{Chent et al., 2019} & \mbox{Chin} & \mbox{This} & Thi$		Korea	TE5	32 (0-24)	(1.20	5	21	0	15	
$ \begin{array}{c} \mbox{Cho et al}, 2007 & South & hos & 50.5 & hos & $	Chen et al., 2019 Chen et al. 2020	China Taiwan	YES	112(37-75) 35(13-22)	64.29 56.1	52 12	60 17	0	15 12	DP DP
		South	NO	00 (10 22)	50.1	14	22	2	12	
	Cho et al., 2017	Korea	NO	39 (12-27)	59	14	22	3	45	DP
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Cohen et al., 2009	Brazil	NO	26(12-14)	57	7	10	7	12	DP
	Davids et al., 2020	USA India	YES NO	75 (N/A) 52 (24 20)	59.9 54.3	40	35	0 11	17.6	DP
	Erasmo et al., 2017	Italy	NO	33(24-29) 81(39-42)	56	7	40	35	32	DP
	Falez et al., 2019	Italy	NO	76 (26-50)	68.5	3	35	38	12	DS
Pattoretio et al., 2016ItalyNO $55 (17-38)$ 63.4 0 16 39 21.5 DP'/DS Frazer et al., 2020NorwayYES $60 (8-21)$ 56 13 12 2 13 DP Geiger et al., 2017GermanyNO $28 (8-20)$ 60.7 8 12 8 25.2 DP George et al., 2017TurkeyNO $35 (25-10)$ 52 12 21 14 6 DP Gractelli et al., 2013BrazilNC $40 (12-28)$ 61.8 16 22 2 12 DP Gractelli et al., 2008SwitzerlandNO $31 (11-20)$ 62 8 13 10 19 DP Hengg et al., 2019AustriaYES $34 (8-29)$ 76 5 17 12 12 DP Jaura et al., 2014IndiaNO $30 (20-10)$ 65 12 14 4 12 DP Kumar et al., 2014IndiaNO $51 (35-16)$ 38 8 15 23 30 DP Kumar et al., 2014IndiaNO $51 (35-16)$ 38 8 15 23 30 DP Launonen et al., 2017SouthYES $31 (11-20)$ 58.6 31 0 0 21 N/A Locarati et al., 2019IrekHead NO $51 (9-37)$ 61.6 N/A N/A N/A Launonen et al., 2019IrekKorea $31 (N/A)$ 5	Faraj et al., 2011	Netherlands	YES	37 (N/A)	N/A	N/A	N/A	N/A	29	DS
Praze et al., 2009OKPKD27 (9-21)39015122151512215DFGeigger et al., 2010GermanyNO28 (8-20)60.7812825.2DPGeigger et al., 2011IndiaNO35 (25-10)521221146DPGonc et al., 2017TurkeyNO31 (12-19)58.44141312DPGracitelli et al., 2013BrazilNO40 (12-28)66.41617012DPHandschine et al., 2014BrazilYES30 (8-25)66.41617012DPHandschine et al., 2014IndiaYES30 (20-10)651214412DPHandschine et al., 2014IndiaYES30 (20-10)651214412DPKitischer et al., 2014IndiaNC30 (11-19)592161216.4DPLaunone et al., 2014IndiaNC31 (12-20)58.6310021N/ALaunone et al., 2017SouthYES31 (11-20)58.6310021N/ALocenze et al., 2020AustriaYES31 (11-20)58.6310021N/ALocenze et al., 2020AustriaYES31 (11-20)58.6310021N/ALocenze et al., 2020Austria	Fattoretto et al., 2016	ltaly	NO	55(17-38)	63.4	0	16	39	21.5	DP/DS
$\begin{array}{c} \mbox{George et al., 2010} & \mbox{George et al., 2021} & \mbox{Ind} & \mbox{NO} & 35 (25-10) & 52 & 12 & 21 & 14 & 6 & DP \\ \mbox{George et al., 2017} & \mbox{Turkey} & \mbox{NO} & 31 (12-19) & 58.4 & 4 & 14 & 13 & 12 & DP \\ \mbox{Gracielli et al., 2013} & \mbox{Brazil} & \mbox{NO} & 40 (12-28) & 61.8 & 16 & 22 & 2 & 12 & DP \\ \mbox{Gracielli et al., 2016} & \mbox{Brazil} & \mbox{NO} & 31 (12-19) & 58.4 & 4 & 14 & 13 & 12 & DP \\ \mbox{Handschine tal., 2008} & \mbox{Switzerland} & \mbox{NO} & 31 (11-20) & 62 & 8 & 13 & 10 & 19 & DP \\ \mbox{Handschine tal., 2019} & \mbox{Austria} & \mbox{YES} & 30 (20-10) & 65 & 12 & 14 & 4 & 12 & DP \\ \mbox{Kuikasis et al., 2010} & \mbox{Austria} & \mbox{YES} & 30 (20-10) & 65 & 12 & 14 & 4 & 12 & DP \\ \mbox{Kuukasis et al., 2006} & \mbox{Germany} & \mbox{NO} & 20 (11-19) & 59 & 2 & 16 & 12 & 16.4 & DP \\ \mbox{Kuukasis et al., 2006} & \mbox{Germany} & \mbox{NO} & 20 (1-19) & 59 & 2 & 16 & 12 & 16.4 & DP \\ \mbox{Kuumar et al., 2014} & \mbox{India} & \mbox{YES} & 31 (13-20) & 58.6 & 31 & 0 & 0 & 21 & \mbox{N/A} \\ \mbox{Lee et al., 2017} & \mbox{Korea} & \mbox{YES} & 31 (11-20) & 58.6 & 31 & 0 & 0 & 21 & \mbox{N/A} \\ \mbox{Lec et al., 2019} & \mbox{Lustria} & \\mbox{YES} & 32 (9-23) & 61.6 & \mbox{N/A} & \mbox{N/A} & \mbox{N/A} & \mbox{Lec et al., 2019} & \mbox{Austria} & \\mbox{YES} & 32 (3-23) & 61.6 & \mbox{N/A} & \mbox{N/A} & \\mbox{N/A} & \\mbox{Lec et al., 2019} & \\mbox{Austria} & \\mbox{YES} & 32 (63-23) & 73 & 0 & 9 & 15 & 40 & DP \\ \mbox{Mutrier et al., 2020} & \mbox{Iualy} & \\mbox{YES} & 32 (1-27) & 62 & 13 & 32 & 27 & 19 & DP \\ \mbox{Mutrier et al., 2010} & \\mbox{Austria} & \\mbox{YES} & 30 (13-27) & 62 & 13 & 22 & \\mbox{N/A} & \\mbox{N/A} & \\mbox{DP} \\ \mbox{Mutrier et al., 2012} & \\mbox{Brazil} & \\mbox{NO} & 58 (63-27) & 73 & 0 & 9 & 15 & 40 & DP \\ \mbox{Mutrier et al., 2012} & \\mbox{Brazil} & \\mbox{NO} & 58 (63-27) & 73 & 23 & 22 & \\mbox{DP} \\ \mbox{Mutrier et al., 2012} & \\mbox{Brazil} & \\mbox{NO} & 58 (63-27) & 73 & 2 & 32 & 27 & 19 & DP \\ $	Fazar et al., 2009 Fraser et al. 2020	Norway	YES	$\frac{27}{60} (8-52)$	56 74 7	15	12 29	31	15 24	DP
	Geiger et al., 2010	Germany	NO	28(8-20)	60.7	8	12	8	25.2	DP
	George et al., 2021	India	NO	35 (25–10)	52	12	21	14	6	DP
	Gonc et al., 2017	Turkey	NO	31(12-19)	58.4	4	14	13	12	DS
	Gracitelli et al., 2013 Gracitelli et al. 2016	Brazil	NO VES	40(12-28) 33(8-25)	61.8 66.4	16 16	22 17	2	12	DP
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Handschin et al., 2008	Switzerland	NO	31(11-20)	62	8	13	10	12	DP
Jaura et al., 2014IndiaYES30 (20-10)651214412DPKlitscher et al., 2006GerenaryNO30 (11-19)592161216.4DPKoukakis et al., 2006GreeceNO20 (8-12)61.7511416.2DPKumar et al., 2014IndiaNO51 (35-16)3888152330DPLaunonen et al., 2017SouthYES31 (11-20)58.6310021N/ALee et al., 2017KoreaKorea13 (1/A)590121912DPLucrat et al., 2020AustriaYES26 (3-23)73091540DPLucrat et al., 2020ItalyYES26 (3-23)73091540DPMatrice et al., 2013CroatiaNO59 (9-50)70.50322719DPMiyazaki et al., 2012BrazilNO33 (14-19)571713424DPMoroteiro et al., 2017UKNO37 (27-10)50.11320412N/ANorouzi et al., 2014GermanyNO26 (6-20)67017920.1DSOckert et al., 2015GermanyNO26 (10-20)67017920.1DSOckert et al., 2015GermanyNO52 (72-5)77.14 <td>Hengg et al., 2019</td> <td>Austria</td> <td>YES</td> <td>34 (5-29)</td> <td>76</td> <td>5</td> <td>17</td> <td>12</td> <td>12</td> <td>DP</td>	Hengg et al., 2019	Austria	YES	34 (5-29)	76	5	17	12	12	DP
Kitscher et al., 2008GermanyNO $30(11-19)$ 39 2 16 12 16.4 DP Koukakis et al., 2016IndiaNO $51(35-16)$ 38 8 15 23 30 DPLaunonen et al., 2017KoreaYES $44(3-41)$ 82 44 0 0 24 N/A Lee et al., 2017KoreaYES $31(11-20)$ 58.6 31 0 0 21 N/A Leonard et al., 2009IrelandNO $32(9-23)$ 61.6 N/A N/A 14 DPLorenz et al., 2020AustriaYES $31(N/A)$ 59 0 12 19 12 DPLuC.Lari et al., 2020AustriaYES $26(3-23)$ 73 0 9 15 40 DPMatrinez et al., 2013CroatiaNO $58(31-27)$ 61 0 33 25 15 DPMinatiro et al., 2011BrazilNO $56(19-37)$ 62 13 28 8 12 DPMonetiro et al., 2011BrazilNO $33(14-19)$ 57 17 13 4 24 DPMonot et al., 2017UKNO $32(27-10)$ 59.9 0 20 12 11 DPNorouzi et al., 2014GermanyNO $26(6-20)$ 67 0 17 9 20.1 DSObret et al., 2015GermanyNO $26(6-20)$ 67 0 17 9 <	Jaura et al., 2014	India	YES	30(20-10)	65	12	14	4	12	DP
Kumar et al., 2010GreeceNO 20 (b-12) 01.7 3 11 4 40.2 $D1$ Launonen et al., 2019UKYES 44 (3-41) 82 44 0 0 24 N/ALee et al., 2017KoreaYES 31 (11-20) 58.6 31 0 0 21 N/ALeonard et al., 2020IrelandNO 32 (9-23) 61.6 N/AN/AN/A 14 DPLorenz et al., 2020AustriaYES 26 (3-23) 73 0 9 15 40 DPMartinez et al., 2020ItalyYES 26 (3-23) 73 0 9 15 40 DPMatrinez et al., 2012BrazilNO 58 (31-27) 61 0 33 25 15 DPMiyazaki et al., 2012BrazilNO 56 (19-37) 62 13 28 8 12 DPMonoret et al., 2011BrazilNO 33 (14-19) 57 17 13 4 24 DPMonoret et al., 2012IranNO 33 (12-21) 59.9 0 20 12 11 DPNorouzi et al., 2014GermanyNO 43 (12-31) 58.2 N/A N/A N/A 12 DPMonoret et al., 2015GermanyNO 50 (10-40) 75 50 0 0 N/A DPOrtrade et al., 2015GermanyNO 22 (12-17) 62.3 0	Klitscher et al., 2008 Koukakis et al. 2006	Germany	NO	30(11-19) 20(8, 12)	59 61 7	2	16 11	12	16.4 16.2	DP
Lauronen et al., 2019UKYES $44(3-41)$ 82 44 0024N/ALee et al., 2017South KoreaYES $31(11-20)$ 58.6 31 0021N/ALeonard et al., 2009IrelandNO $32(9-23)$ 61.6 N/AN/AN/A14DPLorenz et al., 2020AustriaYES $31(N/A)$ 59 0121912DPLuc.Lani et al., 2020ItalyYES $26(3-23)$ 73091540DPMartinez et al., 2019SpainNO $58(31-27)$ 61 0 33 2515DPMatejC.Lc et al., 2013CroatiaNO $59(9-50)$ 70.5 0 32 2719DPMiyazaki et al., 2012BrazilNO $56(19-37)$ 62 1328812DPMonteiro et al., 2011BrazilNO $32(9-23)$ 59.9 0201211DPMoonot et al., 2012IranNO $32(27-10)$ 50.1 13204120DPOckert et al., 2014GermanyNO $43(12-31)$ 58.2 N/AN/AN/A120DPOrtmaier et al., 2015GermanyNO $26(6-20)$ 67 017 9 20.1DSOleru dt al., 2010GermanyNO $52(10-42)$ 75 00N/ADPOrtmaier et al., 2015AustriaYES	Kumar et al., 2014	India	NO	51(35-16)	38	8	15	23	30	DP
Lee et al., 2017South KoreaYES $31(11-20)$ 58.6 31 0 0 21 N/ALeonard et al., 2009IrelandNO $32(9-23)$ 61.6 N/AN/AN/A14DPLorenz et al., 2020AustriaYES $31(N/A)$ 59 0 12 19 12 DPLucLiani et al., 2020HalyYES $26(3-23)$ 73 0 9 15 40 DPMattinez et al., 2013CroatiaNO $58(31-27)$ 61 0 33 25 15 DPMitazaki et al., 2012BrazilNO $56(19-37)$ 62 13 28 8 12 DPMonteiro et al., 2011BrazilNO $33(14-19)$ 57 17 13 4 24 DPMonot et al., 2017UKNO $32(9-23)$ 59.9 0 20 12 11 DPNorouzi et al., 2014GermanyNO $43(12-31)$ 58.2 N/A N/A 120 DPOth et al., 2014GermanyNO $26(6-20)$ 67 0 17 9 20.1 DSOlerud et al., 2015AustriaYES $30(13-17)$ 31.3 0 10 20 38.4 N/A Papadopoulos et al., 2009GreeceNO $29(12-17)$ 62.3 0 22 7 17.9 DPParamaksizoglu et al., 2010TurkeyNO $32(10-22)$ 67 0 17.9	Launonen et al., 2019	UK	YES	44 (3-41)	82	44	0	0	24	N/A
Leonard et al., 2009 Ireland NO 32 (9–23) 61.6 N/A N/A N/A I DP Lorenz et al., 2020 Austria YES 31 (N/A) 59 0 12 19 12 DP LuC.Lani et al., 2020 Italy YES 26 (3–23) 73 0 9 15 40 DP Martinez et al., 2009 Spain NO 58 (31–27) 61 0 33 25 15 DP Matriez et al., 2012 Brazil NO 56 (19–37) 62 13 28 8 12 DP Monteiro et al., 2011 Brazil NO 32 (9–23) 59.9 0 20 12 11 DP Moonot et al., 2017 Iran NO 32 (9–23) 59.9 0 20 12 11 DP More et al., 2012 Iran NO 32 (7–27.10) 50.1 13 20 4 12 N/A Ockert et al., 2010 <td< td=""><td>Lee et al., 2017</td><td>South</td><td>YES</td><td>31(11-20)</td><td>58.6</td><td>31</td><td>0</td><td>0</td><td>21</td><td>N/A</td></td<>	Lee et al., 2017	South	YES	31(11-20)	58.6	31	0	0	21	N/A
Lorent et al., 2009InternationNC52 (5)100N/AN/AN/A14DFLuC.Lani et al., 2020ItalyYES 26 (3-23)73091540DPMartinez et al., 2009SpainNO 58 (31-27)610332215DPMatejC.Lc et al., 2013CroatiaNO 59 (9-50)70.50322719DPMiyazaki et al., 2012BrazilNO 56 (19-37)621328812DPMontior et al., 2011BrazilNO 33 (14-19)571713424DPMoonot et al., 2007UKNO 32 (9-23)59.90201211DPNorouzi et al., 2012IranNO 37 (27-10)50.11320412N/AOckert et al., 2014GermanyNO 26 (6-20)67017920.1DPOft et al., 2010SwedenNO 50 (10-40)755000N/ADPOrtmaier et al., 2015AustriaYES 32 (7-25)77.1424412.8DP/DSParadopoulos et al., 2010IndiaYES 20 (210-12)630122025DPParadopoulos et al., 2010IndiaYES 20 (210-25)77.1424412.8DP/DSParadopoulos et al., 2020IndiaYES </td <td>Leonard et al. 2009</td> <td>Korea Ireland</td> <td>NO</td> <td>32(9-23)</td> <td>61.6</td> <td>N/A</td> <td>NI / A</td> <td>N/A</td> <td>14</td> <td>ΠP</td>	Leonard et al. 2009	Korea Ireland	NO	32(9-23)	61.6	N/A	NI / A	N/A	14	ΠP
LuC.Lani et al., 2020ItalyYES 26 ($3-23$) 73 0 9 15 40 DPMattinez et al., 2009SpainNO 58 ($31-27$) 61 0 33 25 15 DPMatejC.L c et al., 2013CroatiaNO 59 ($9-50$) 70.5 0 32 27 19 DPMiyazaki et al., 2012BrazilNO 56 ($19-37$) 62 13 28 8 12 DPMonteiro et al., 2017BrazilNO 33 ($14-19$) 57 17 13 4 24 DPMonot et al., 2007UKNO 32 ($9-23$) 59.9 0 20 12 11 DPNorouzi et al., 2012IranNO 37 ($27-10$) 50.1 13 20 4 12 N/A Ockert et al., 2014GermanyNO 43 ($12-31$) 58.2 N/A N/A N/A 120 DPOh et al., 2015GermanyNO 46 ($6-20$) 67 0 17 9 20.1 DSOlerud et al., 2015AustriaYES 30 ($10-40$) 75 50 0 0 N/A DPOrtmaier et al., 2010SwedenNO 50 ($10-40$) 75 50 0 0 N/A DPParadopoulos et al., 2010GreeceNO 32 ($10-22$) 63 0 12 20 25 DPPatadopoulos et al., 2010TurkeyNO 32 ($10-2$	Lorenz et al., 2009	Austria	YES	31 (N/A)	59	0	12	19	12	DP
Martinez et al., 2009SpainNO58 (31–27)610332515DPMatejC.L et al., 2013CroatiaNO $59 (9-50)$ 70.5 0 32 27 19DPMiyazaki et al., 2012BrazilNO $56 (19-37)$ 62 1328812DPMonteiro et al., 2011BrazilNO $33 (29-23)$ 59.9 0 20 1211DPMoonot et al., 2007UKNO $32 (9-23)$ 59.9 0 20 1211DPNorouzi et al., 2012IranNO $37 (27-10)$ 50.1 13 20 412N/AOckert et al., 2015GermanyNO $43 (12-31)$ 58.2 N/AN/AN/A120DPOh et al., 2015GermanyNO $26 (10-40)$ 75 50 00N/ADPOtruaier et al., 2015AustriaYES $32 (10-22)$ 63 012 20 25 DPPapadopoulos et al., 2010TurkeyNO $32 (10-22)$ 63 012 20 25 DPPath et al., 2010GermanyYES $32 (10-22)$ 63 012 20 25 DPPath et al., 2010TurkeyNO $32 (10-22)$ 63 012 20 25 DPPath et al., 2010ScotlandNO $47 (21-26)$ 57 27 12 8 24 DSSeo et al.,	LuC.I.ani et al., 2020	Italy	YES	26 (3-23)	73	Õ	9	15	$\overline{40}$	DP
MategC_Lc et al., 2013CroatiaNO59 (9–50)70.50322719DPMiyazaki et al., 2012BrazilNO56 (19–37)621328812DPMonteiro et al., 2001BrazilNO33 (14–19)571713424DPMonoot et al., 2007UKNO32 (9–23)59.90201211DPNorouzi et al., 2012IranNO37 (27–10)50.11320412N/AOckert et al., 2014GermanyNO26 (6–20)67017920.1DSOlerud et al., 2015GermanyNO26 (6–20)670102038.4N/APapadopoulos et al., 2010SwedenNO50 (10–40)755000N/ADPOrtmaier et al., 2015AustriaYES30 (13–17)31.30102038.4N/APapadopoulos et al., 2010GreeceNO29 (12–17)62.3022717.9DPPratmaksizoglu et al., 2010GermanyYES32 (7–25)77.1424412.8DP/DSPrajapati et al., 2010ScotlandNO47 (21–26)572712824DSSeo et al., 2020IndiaYES20 (5–15)41N/AN/AN/A12DP/DSSetaro et al., 2020ItalyYES64 (N	Martinez et al., 2009	Spain	NO	58 (31-27)	61	0	33	25	15	DP
Minyazari et al., 2012 Diazli NO 33 (14–19) 52 15 23 5 12 Di Diazli Di Diazli Di Diazli Di Diazli Di Diazli Di Diazli Di Diazli Diazli Di Dia	MatejC.I.c et al., 2013 Miyazaki et al. 2012	Croatia	NO	59(9-50) 56(19-37)	70.5	0 13	32	27	19	DP
Moonot et al., 2007UKNO $32(9-23)$ 59.9 0 20 12 11 DPNorouzi et al., 2012IranNO $37(27-10)$ 50.1 13 20 4 12 N/A Ockert et al., 2014GermanyNO $43(12-31)$ 58.2 N/A N/A N/A 120 DPOh et al., 2015GermanyNO $26(6-20)$ 67 0 17 9 20.1 DSOlerud et al., 2010SwedenNO $50(10-40)$ 75 50 0 0 N/A DPOrtmaier et al., 2015AustriaYES $30(13-17)$ 31.3 0 10 20 38.4 N/A Papadopoulos et al., 2009GreeceNO $29(12-17)$ 62.3 0 22 7 17.9 DPParadsizoglu et al., 2010TurkeyNO $32(7-25)$ 77.1 4 24 4 12.8 DP/DSPrajapati et al., 2020IndiaYES $32(7-25)$ 77.1 4 24 4 12.8 DP/DSRobinson et al., 2010ScotlandNO $47(21-26)$ 57 27 12 8 24 DSSeo et al., 2020KoreaNO $27(12-15)$ 53 5 14 8 15.9 DPShahid et al., 2008UKNO $41(9-32)$ N/A 11 11 19 12 DPShi et al., 2021KoreaNO $56(12-44)$ 74.3 21 <td>Monteiro et al., 2012</td> <td>Brazil</td> <td>NO</td> <td>33(14-19)</td> <td>57</td> <td>17</td> <td>13</td> <td>4</td> <td>24</td> <td>DP</td>	Monteiro et al., 2012	Brazil	NO	33(14-19)	57	17	13	4	24	DP
Norouzi et al., 2012IranNO $37 (27-10)$ 50.1 13 20 4 12 N/AOckert et al., 2014GermanyNO $43 (12-31)$ 58.2 N/AN/AN/A120DPOh et al., 2015GermanyNO $26 (6-20)$ 67 0 17 9 20.1 DSOlerud et al., 2010SwedenNO $50 (10-40)$ 75 50 00N/ADPOrtmaier et al., 2015AustriaYES $30 (13-17)$ 31.3 0 10 20 38.4 N/APapadopoulos et al., 2009GreeceNO $29 (12-17)$ 62.3 0 22 7 17.9 DPParmaksizoglu et al., 2010TurkeyNO $32 (10-22)$ 63 0 12 20 25 DPPlath et al., 2019GermanyYES $32 (7-25)$ 77.1 4 24 4 12.8 DP/DSPrajapati et al., 2010ScotlandNO $47 (21-26)$ 57 27 12 8 24 DSSeo et al., 2020IndiaYES $64 (N/A)$ 61.5 37 27 0 48 DPShahid et al., 2011ChinaNO $43 (15-28)$ 68.7 10 21 12 DPShi et al., 2021SouthNO $56 (12-44)$ 74.3 21 27 8 15.4 DPSiebenbürger et al., 2019GermanyYES $55 (12-43)$ 76.6 20 22 <	Moonot et al., 2007	UK	NO	32 (9-23)	59.9	0	20	12	11	DP
Ockert et al., 2014 Germany NO 43 (12–31) 58.2 N/A N/A N/A 120 DP Oh et al., 2015 Germany NO 26 (6–20) 67 0 17 9 20.1 DS Olerud et al., 2010 Sweden NO 50 (10–40) 75 50 0 0 N/A DP Ortmaier et al., 2015 Austria YES 30 (13–17) 31.3 0 10 20 38.4 N/A Papadopoulos et al., 2009 Greece NO 32 (10–22) 63 0 12 20 25 DP Plath et al., 2019 Germany YES 32 (7–25) 77.1 4 24 4 12.8 DP/DS Prajapati et al., 2010 Scotland NO 47 (21–26) 57 27 12 8 24 DS Seo et al., 2020 Italy YES 64 (N/A) 61.5 37 27 0 48 DP Shahid et al., 2020	Norouzi et al., 2012	Iran	NO	37(27-10)	50.1	13	20	4	12	N/A
Offer al., 2015 Germany NO 20 (0-20) 67 6 17 7 20.1 D3 Olerud et al., 2015 Austria YES 30 (13-17) 31.3 0 10 20 38.4 N/A Papadopoulos et al., 2009 Greece NO 29 (12-17) 62.3 0 22 7 17.9 DP Parmaksizoglu et al., 2010 Turkey NO 32 (10-22) 63 0 12 20 25 DP Plath et al., 2019 Germany YES 32 (7-25) 77.1 4 24 4 12.8 DP/DS Prajapati et al., 2010 Scotland NO 47 (21-26) 57 27 12 8 24 DF Seo et al., 2020 India YES 20 (5-15) 41 N/A N/A N/A 12 DP/DS Setaro et al., 2020 Korea NO 27 (12-15) 53 5 14 8 15.9 DP Shahid et al., 2001 Italy YES 64 (N/A) 61.5 37 27 0	Ockert et al., 2014 Ob at al., 2015	Germany	NO	43(12-31)	58.2 67	N/A	N/A 17	N/A	120	DP
Ortmaier et al., 2015 Austria YES 30 (13-17) 31.3 0 10 20 38.4 N/A Papadopoulos et al., 2009 Greece NO 29 (12-17) 62.3 0 22 7 17.9 DP Parmaksizoglu et al., 2010 Turkey NO 32 (10-22) 63 0 12 20 25 DP Plath et al., 2019 Germany YES 32 (7-25) 77.1 4 24 4 12.8 DP/DS Prajapati et al., 2020 India YES 20 (5-15) 41 N/A N/A N/A Robinson et al., 2010 Scotland NO 47 (21-26) 57 27 12 8 24 DS Seo et al., 2020 Korea NO 27 (12-15) 53 5 14 8 15.9 DP Shahid et al., 2020 Italy YES 64 (N/A) 61.5 37 27 0 48 DP Shahid et al., 2008 UK	Olerud et al., 2010	Sweden	NO	50(10-40)	75	50	0	0	20.1 N/A	DP
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Ortmaier et al., 2015	Austria	YES	30 (13-17)	31.3	0	10	20	38.4	N/A
Parmaksizoglu et al., 2010TurkeyNO $32 (10-22)$ 63 0 12 20 25 DPPlath et al., 2019GermanyYES $32 (7-25)$ 77.1 4 24 4 12.8 DP/DSPrajapati et al., 2020IndiaYES $20 (5-15)$ 41 N/AN/AN/A 12 DP/DSRobinson et al., 2010ScotlandNO $47 (21-26)$ 57 27 12 8 24 DSSeo et al., 2020SouthNO $27 (12-15)$ 53 5 14 8 15.9 DPSetaro et al., 2020ItalyYES $64 (N/A)$ 61.5 37 27 0 48 DPShahid et al., 2008UKNO $41 (9-32)$ N/A 11 11 19 12 DPShi et al., 2011ChinaNO $43 (15-28)$ 68.7 10 21 12 DPShin et al., 2021South KoreaNO $56 (12-44)$ 74.3 21 27 8 15.4 DPSiebenbürger et al., 2019GermanyYES $55 (12-43)$ 76.6 20 22 13 24 DPSohn et al., 2017South KoreaYES $90 (N/A)$ 61.8 35 44 11 14.7 DP/DS	Papadopoulos et al., 2009	Greece	NO	29 (12-17)	62.3	0	22	7	17.9	DP
IndifferenceProduct al., 2017GermanyPES $32 (7-23)$ 77.1 4 24 4 12.8 DP/DS Prajapati et al., 2020IndiaYES $20 (5-15)$ 41 N/AN/AN/A 12 DP/DS Robinson et al., 2010ScotlandNO $47 (21-26)$ 57 27 12 8 24 DS Seo et al., 2020SouthNO $27 (12-15)$ 53 5 14 8 15.9 DP Setaro et al., 2020ItalyYES $64 (N/A)$ 61.5 37 27 0 48 DP Shahid et al., 2008UKNO $41 (9-32)$ N/A 11 11 19 12 DP Shi et al., 2011ChinaNO $43 (15-28)$ 68.7 10 21 12 DP Shin et al., 2021SouthNO $56 (12-44)$ 74.3 21 27 8 15.4 DP Siebenbürger et al., 2019GermanyYES $55 (12-43)$ 76.6 20 22 13 24 DP Sohn et al., 2017SouthYES $90 (N/A)$ 61.8 35 44 11 14.7 DP/DS	Parmaksizoglu et al., 2010	Turkey	NO VES	32(10-22)	63 77 1	0	12	20	25 12 8	DP DP
Robinson et al., 2010 Scotland NO 47 (21-26) 57 27 12 8 24 DS Seo et al., 2020 South NO 27 (12-15) 53 5 14 8 15.9 DP Setaro et al., 2020 Italy YES 64 (N/A) 61.5 37 27 0 48 DP Shahid et al., 2008 UK NO 41 (9-32) N/A 11 11 19 12 DP Shahid et al., 2011 China NO 43 (15-28) 68.7 10 21 12 DP Shin et al., 2021 South NO 56 (12-44) 74.3 21 27 8 15.4 DP Siebenbürger et al., 2019 Germany YES 55 (12-43) 76.6 20 22 13 24 DP Sohn et al., 2017 South YES 90 (N/A) 61.8 35 44 11 14.7 DP/DS	Praiapati et al., 2019 Praiapati et al. 2020	India	YES	32(7-25) 20(5-15)	41	N/A	24 N/A	N/A	12.0	DP/DS
Seo et al., 2020South KoreaNO $27(12-15)$ 53 5 14 8 15.9 DPSetaro et al., 2020ItalyYES $64(N/A)$ 61.5 37 27 0 48 DPShahid et al., 2008UKNO $41(9-32)$ N/A 11 11 19 12 DPShi et al., 2011ChinaNO $43(15-28)$ 68.7 10 21 12 DPShin et al., 2021South KoreaNO $56(12-44)$ 74.3 21 27 8 15.4 DPSiebenbürger et al., 2019GermanyYES $55(12-43)$ 76.6 20 22 13 24 DPSohn et al., 2017South KoreaYES $90(N/A)$ 61.8 35 44 11 14.7 DP/DS	Robinson et al., 2010	Scotland	NÖ	47 (21-26)	57	27	12	8	24	DS
Korea Korea <th< td=""><td>Seo et al., 2020</td><td>South</td><td>NO</td><td>27 (12-15)</td><td>53</td><td>5</td><td>14</td><td>8</td><td>15.9</td><td>DP</td></th<>	Seo et al., 2020	South	NO	27 (12-15)	53	5	14	8	15.9	DP
Scharb et al., 2020 Hary HES OF (N/A) 61.5 57 27 0 48 DP Shahid et al., 2008 UK NO 41 (9–32) N/A 11 11 19 12 DP Shi et al., 2011 China NO 43 (15–28) 68.7 10 21 12 DP Shin et al., 2021 South Korea NO 56 (12–44) 74.3 21 27 8 15.4 DP Siebenbürger et al., 2019 Germany YES 55 (12–43) 76.6 20 22 13 24 DP Sohn et al., 2017 South Korea YES 90 (N/A) 61.8 35 44 11 14.7 DP/DS	Sotaro et al 2020	Korea	VEC	64 (N / A)	61 5	27		0	19	 90
Shi et al., 2011 China NO 43 (15-28) 68.7 10 21 12 12 DP Shin et al., 2021 South Korea NO 56 (12-44) 74.3 21 27 8 15.4 DP Siebenbürger et al., 2019 Germany YES 55 (12-43) 76.6 20 22 13 24 DP Sohn et al., 2017 Korea YES 90 (N/A) 61.8 35 44 11 14.7 DP/DS	Shahid et al., 2020	UK	NO	41(9-32)	N/A	11	11	19	40 12	DP
Shin et al., 2021 South Korea NO 56 (12-44) 74.3 21 27 8 15.4 DP Siebenbürger et al., 2019 Germany YES 55 (12-43) 76.6 20 22 13 24 DP Sohn et al., 2017 Korea YES 90 (N/A) 61.8 35 44 11 14.7 DP/DS	Shi et al., 2011	China	NŎ	43 (15-28)	68.7	10	21	12	12	DP
Siebenbürger et al., 2019 Germany YES 55 (12–43) 76.6 20 22 13 24 DP Sohn et al., 2017 Korea YES 90 (N/A) 61.8 35 44 11 14.7 DP/DS	Shin et al., 2021	South	NO	56(12-44)	74.3	21	27	8	15.4	DP
Sobelinger et al., 2017 Germany TES 35 (12-45) 76.6 20 22 15 24 DP Sohn et al., 2017 South YES 90 (N/A) 61.8 35 44 11 14.7 DP/DS	Siehenhümzen et al. 2010	Korea	VEC	55 (12 42)	76.6	20		12	24	קרו
Sonn et al., 2017 Korea YES 90 (N/A) 61.8 35 44 11 14.7 DP/DS	Siebenburger et al., 2019	South	1E3	33(12-43)	/0.0	20	<u></u>	13	2 4	
Notca	Sonn et al., 2017	Korea	YES	90 (N/A)	61.8	35	44	11	14./	DP/DS

Table 1. Details of the included studies; Pt. patients, M male, F female, N Neer Classification, DS delto-split, DP delto-pectoral.

Einst Assthese Mese	Country	Commonativo		1	Neer Classification		ation	Mean	Surgical
First Author; fear	Country	Comparative	Pt. (M-F)	Age	N2	N3	N4	Follow-Up	Approach
Spross et al., 2012	Switzerland	YES	22 (4-18)	75	N/A	N/A	N/A	30	DP
Spross et al., 2012	Switzerland	NO	294 (71-223)	72.9	N/A	N/A	N/A	12	DP
Trepat et al., 2012	Spain	YES	11 (3-8)	68.3	11	0	0	6	DP
Urda et al., 2012	Spain	NO	15 (3-12)	71	15	0	0	40.67	DP
Vijan et al., 2020	India	YES	15 (N/A)	52.3	7	6	2	12	N/A
Vijayvargiya et al., 2016	India	NO	26 (19-7)	46	5	12	9	12	DS
Voigt et al., 2011	Germany	YES	31 (N/A)	72	0	27	4	12	DP
Wang et al., 2019	China	YES	46 (13-33)	72.5	0	0	46	19	DP
Xue et al., 2018	China	YES	43(N/A)	57	43	0	0	N/A	DS
Zeng et al., 2018	China	YES	181 (64-117)	57.4	78	75	28	12	DP
Zhao et al., 2019	China	YES	21 (12-9)	69	0	15	6	12	DP

Table 1. Cont.

3.2. Complications and Reinterventions

One study did not report the number of complications. In the remaining 77 studies, 1229 complications were described. Fifty-seven studies (3187 patients) reported the complication rate, which was 23.8%.

The most frequent complication was screw perforation into the joint/screw cut-out in 306 patients, with a rate of 4.1% (95% C.I. 3.2–5.1%) representing 25.7% of all complications, followed by AVN of the humeral head in 214 patients with a rate of 3.1% (95% C.I. 2.4–3.9%), representing 17.9% of all complications. The third most common complication was sub-acromial impingement in 121patients with a rate of 1.5% (95% C.I. 1.1–2.0%), accounting for 10.1% of all complications (Table 2) (Figure 2).

Twenty-three studies (1290 patients) reported the type of fracture in which the complication occurred, described using the Neer classification. For Neer type 4 fractures the complication rate was 38.8%, while in Neer type 3 it was 5.8% and in Neer type 2 it was 8.9%.

Tab	le 2.	Comp	lication	type; n°	and	l rate of	comp	lications.
-----	-------	------	----------	----------	-----	-----------	------	------------

Complication Type	\mathbf{N}° of Complications	Complication Rate	% of the Total
Total complications	1229	29.1	100%
Cut-out	313	7.5	25.7%
AVN	215	5.1	17.6%
Subacromial Impingement	121	2.9	9.9%
Non-union	79	1.9	6.4%
Fixation Loss	76	1.8	6.3%
Pain	70	1.6	5.7%
Others	65	1.5	5.3%
Varus collapse	45	1.1	3.6%
Stiffness	41	0.9	3.1%
Deep Infection	34	0.8	2.8%
Malunion	36	0.8	2.9%
Nerve Injury	30	0.7	2.4%
Failure	20	0.5	1.6%
Superficial Infection	15	0.4	1.2%
Malreduction	14	0.3	1.2%
Screw-back	7	0.2	0.6%
Plate Breaking	4	0	0.3%
Unknown	42	1	3.4%



Figure 2. Complications and reinterventions causes; data reported as percentages of the total complications and reinterventions.

A total of 59 studies (3210 patients) reported the number of reinterventions performed after PHILOS plating. There was a total of 514 reinterventions on 441 patients, and the reintervention rate was 10.5% (95% C.I. 8.3–12.8%). The most common cause of reintervention was screw cut-out, followed by AVN of the humeral head and subacromial impingement (Table 3).

Table 3. Reasons for reintervention; n° and rate of reinterventions.

Reintervention Reason	N $^\circ$ of Reinterventions	Reintervention Rate	% of the Total
Total Reintervention	514	16	100
Cut-out	69	2.2	13.4
AVN	61	1.9	11.9
Subacromial	52	17	10.2
Impingement	55	1.7	10.5
Pt will	37	1.2	7.2
Failure	18	0.6	3.5
Loss Fixation	17	0.5	3.3
Deep Infection	13	0.4	2.5
Non-Union	10	0.3	2.0
Pain	8	0.2	1.6
Varus Collapse	8	0.2	1.6
Other	8	0.2	1.6
Mal Reduction	7	0.2	1.5
Stiffness	5	0.2	0.9
Plate Discomfort	5	0.2	0.9
Malunion	2	0	0.4
Frozen Shoulder	2	0	0.4
Screw Back	2	0	0.4
Nerve Injury	1	0	0.2
Plate Break	1	0	0.2
Unknown	187	5.8	36.2

A total of 46 studies reported both the type of complications and the reason for reinterventions: the complications with the highest probability of reintervention was plate break (100% of the affected patients), followed by malreduction in 87.5% of the affected patients, subacromial impingement (73.6%), and loss of fixation (56.5%) (Table 4).

Type of Complications	% of Complication Causing Reintervention
Cut-out	32.5
AVN	35.9
Subacromial impingement	73.6
Pain	8.4
Loss fixation	56.5
Non-union	26.3
Other	25.0
Varus collapse	25.8
Deep infection	33.3
Malunion	8.0
Stiffness	27.8
Nerve injury	10
Malreduction	87.5
Superficial infection	0.0
Screw-back	0.0
Plate breaking	100

Table 4. Probability of reintervention for type of complication.

3.3. Complications and Reinterventions in Deltopectoral and Delto-Split Approaches

The studies in which the DP approach was used reported 710 complications, for a complication rate of 23.8% (95% C.I. 19.9–27.7%) (Table 4). The most common complications were screw cut-out (6.8%) and AVN of the humeral head (5.2%). These two complications accounted for 44% of the total complications. The rate of complications in the DS approach was 17.5% (95% C.I. 12.6–22.3%) (137 complications) (Table 5). Furthermore, for this approach screw cut-out and AVN of the humeral head were the two most common complications, accounting for 39.2% of all complications.

Table 5. Details Pt with Complications and Reintervention.

	Pt. with Complications	N° of Complications	Complications Rate	Pt. with Reintervention	N° of Reintervention	Reintervention Rate
>55 years	836	347	29.5	761	216	19.0
DP group	2910	810	23.8	2301	291	8.6
DS group	657	137	17.5	398	53	10.4
Pt. tot	4200	1229	23.8	3210	514	10.5

To better comprehend the relationship between surgical approach and complications for each fracture type, these two groups were divided into subgroups according to the fracture type. In the Neer 2 group, the complication rate for the DP approach was 10.1% and for the DS approach was 8.5% (95% C.I. 4.5–15.6% vs. 95% C.I. 2.5–14.6%, n.s.). In the Neer type 3 group, the complication rate for the DP approach was 13.5% and for the DS approach was 16.2% (95% C.I. 7.8–19.1% vs. 95% C.I. 2.5–29.9%, n.s.). In the Neer type 4 group, the complication rate for the DP approach was 24.1% and for the DS approach was 25.6% (95% C.I. 16.7–31.5% vs. 0.0–51.1%, n.s.). No differences between the two approaches were seen for any of the abovementioned fracture types (n.s.) (Table 6).

Complication Rate	Neer Type 2	Neer Type 3	Neer Type 4
DP group	$10.1\pm2.8\%$	$13.5\pm2.9\%$	$24.1\pm3.8\%$
Di gioup	(95% C.I. 4.5–15.6)	(95% C.I. 7.8–19.1)	(95% C.I. 16.7–31.5)
DS group	$8.5\pm3.0\%$	$16.2\pm7.0\%$	$25.6\pm7.0\%$
Dogroup	(95% C.I. 2.5–14.6)	(95% C.I. 2.5–29.9)	(95% C.I. 0.0–51.1)
p Value	0.37	0.37	0.39

Table 6. Complication rate normalized for the type of fracture and surgical approach.

Regarding reinterventions, 45 studies (2301 patients) where the DP approach was used reported 291 reinterventions, for a rate of 8.6% (95% C.I. 6.5–10.7%) (Table 5), whereas in the DS approach the reintervention rate was 10.4% (95% C.I. 5.9–14.8%) (10 studies, 398 patients) (n.s.) (Table 4). The most common reasons for reintervention in both approaches were screw cut-out, AVN of the humeral head, and subacromial impingement.

3.4. Complications and Reinterventions in Patients over 55 Years Old

In the 13 articles including only patients over 55 years old, the complication rate was 29.5% (95% C.I. 17.6–41.4%) (347 complications) (Table 4). The most common complications included screw cut-out (35.4% of the complications) and AVN of the humeral head (16.1% of the complications). Moreover, 216 patients underwent reintervention (19.0%, 95% C.I. 9.9–28.1%) with screw cut-out being the main cause (Table 4).

3.5. Functional Outcome

Regarding functional outcomes, the two most used scores in the retrieved papers were the Constant and Murley Score (CMS) [16] and the Disabilities of Arm, Shoulder and Hand (DASH) score [17]. The CMS is divided into four subscales: pain (15 points), activities of daily living (20 points), strength (25 points), and range of motion (40 points); the higher the score, the higher the quality of the function, for a maximum score of 100 points. The DASH score is a 30-item, self-report questionnaire designed to measure physical function and symptoms in patients with several musculoskeletal disorders of the upper limb. It is composed of two parts: the disability/symptom section and the optional sport/music or work section. The overall DASH score ranges from 0 to 100, with 0 being the best possible score. The CMS at \geq 12 months was reported by 39 articles, the mean was 70.8 points (95% C.I. 66.7–74.9 points). According to the CMS, functional outcomes were excellent in 3 studies (7.7%), good in 21 (53.8%), moderate in 13 studies (33.4%), and poor in 2 studies (5.1%). The DASH score at \geq 12 months was reported by 16 articles, and the mean was 20.5 points (95% C.I. 16.6–24.3 points).

3.6. Risk of Bias

The Downs and Black's tools for assessing the risk of bias give each study an excellent ranking for scores \geq 26, good for scores from 20 to 25, fair for scores between 15 and 19, and poor for scores \leq 14 points. According to these criteria, 8 of the included studies were classified poor, 49 fair, 16 good, and 5 excellent (Figure 3). Mostly, the factors reducing the quality of the studies were the absence of confounders and blinding attempts and the low statistical power of some studies.

Acklin et al., 2009 Acklin et al., 2013 Aggarwal. et al., 2010 Aliuddin et al., 2016 Bachelier et al., 2014 Bandalovic et al., 2014 Beeres et al., 2017 Bhayana et al., 2021 Björkenheim et al., 2004 Boesmueller et al., 2016 Borer et al., 2017 Boudard et al., 2014 Bu et al., 2021 Buchmann et al., 2021 Cai et al., 2012 Caliskan et al., 2019 Cha et al., 2017 Chen et al., 2019 Chen et al., 2020 Cho et al., 2017 Cohen et al., 2009 Davids et al., 2020 Doshi et al., 2017 Erasmo et al., 2014 Falez et al., 2019 Faraj et al., 2011 Fattoretto et al., 2016 Fazal. et al., 2009 Fraser et al., 2020 Geiger et al., 2010 George et al., 2021 Gonc et al., 2017 Gracitelli et al., 2013 Gracitelli et al., 2016 Handschin et al., 2008 Hengg et al., 2019 Jaura et al., 2014 Klitscher et al., 2008 Koukakis et al., 2006 Kumar et al., 2014 Launonen et al., 2019 Lee et al., 2017 Leonard et al., 2009 Lorenz et al., 2020 Luciani et al., 2020 Martinez et al., 2009 Mateicic et al., 2013 Miyazaki et al., 2012 Monteiro et al., 2011 Moonot et al., 2007 Norouzi et al., 2012 Ockert et al., 2014 Oh et al., 2015



Figure 3. Cont.

Olerud et al., 2010 Ortmaier et al., 2015 Papadopoulos et al., 2009 Parmaksizoglu et al., 2010 Plath et al., 2019 Prajapati et al., 2020 Robinson et al., 2010 Seo et al., 2020 Setaro et al., 2020 Shahid et al., 2008 Shi et al., 2011 Shin et al., 2021 Siebenbürger et al., 2019 Sohn et al., 2017 Spross et al., 2012 Spross et al. II, 2012 Trepat et al., 2012 Urda et al., 2012 Vijan et al., 2020 Vijayvargiya et al., 2016 Voigt et al., 2011 Wang et al., 2019 Xue et al., 2018 Zeng et al., 2018 Zhao et al., 2019



Figure 3. Downs and Black's tool for assessing the risk of bias. For the explanation of each column question, see Appendix A.

4. Discussion

The main finding of the present study was that proximal humerus synthesis with a PHILOS plate has a high complication rate of 23.8% and a reintervention rate of 10.5% and that these values increase up to 29.5% and 19.0%, respectively, in the over-55 population. The most frequent complication in both population groups was screw cut-out, followed by AVN of the humeral head and subacromial impingement.

Nowadays, the PHILOS plate is the most used method of PHFs fixation. Still, despite PHILOS's large use, the current literature lacks proper investigation of the complication and reintervention rate of this surgical approach. Regarding complication rate in the PHILOStreated population, previous reviews provided discording data: old review attempts of Sproul et al. [18] in 2010 and Kavuri et al. [19] in 2018 reported a complication rate of 32.6% and 32.8%, respectively, while more recent studies showed a wide range of complications going from 12.0% to 43.0% [18,20-24]. Previous reviews also presented important limitations including mixed populations treated with various plate designs. On the opposite, the present systematic review and meta-analysis present data focused on patients treated with PHILOS plate. Thus, this data helps clarify the actual prevalence of complications of the PHILOS plate through an updated and comprehensive synthesis of the literature. In this population, the complication rate was 23.8%. This may seem lower than other reports. For example, Barlow et al. reported a 34% failure rate [25]. However, it is important to consider the inclusion criteria of different studies, as in the study of Barlow et al. the focus was on patients older than 65 years, besides including different plates, which by themselves may entail different results and therefore weight on the conclusions driven. In this meta-analysis, specifically focused on the PHILOS plate, further analysis was performed to better comprehend the relationship between complication rate and age by considering only studies describing patients over 55 years old: in this population, the complication rate raised to 29.5%. This increase in the complication rate is not surprising, because this age range was described to have a 2.6 times higher risk of osteoporosis than the younger one [1,26-39].

The most frequent complication documented in the present study was screw cut-out, with a rate of 4.1%. Moreover, the previous reviews underlined this as the most frequent

complication, with Sproul et al. [18] reporting a rate of 7.5%, and Kavuri et al. [19] of 9.5% in these older literature analyses. In addition, this systematic review and meta-analysis was also able to underline that patients with this type of complication have a 35.6% chance of reintervention. Given the prevalence and dangerous consequences of screw cut-out, it would have been important to further analyze this complication by dividing it into primary and secondary. Primary penetration is caused by an intraoperative surgical error, thus being preventable. This occurs when a too-long screw is inserted, and subsequently, it penetrates the cortical bone to the glenohumeral joint. On the other hand, secondary penetration of the screw into the joint occurs later and can be caused as a result of AVN, varus collapse, or failed fixation. Unfortunately, this subanalysis was not feasible since the available literature is lacking on this aspect and almost no study reported the prevalence of the two types of screw cut-out. Future clinical trials should specifically take into consideration this problem, as it could help to improve patient treatment and clinical outcomes.

AVN of the humeral head is the most dangerous complication and one of the greatest concerns for the surgeon because it necessarily implies a reintervention. It can develop within 5 years from the injury; thus, since only long-term observational studies can detect the true rate, short-term studies could have even underestimated the already high occurrence of this severe complication. AVN can be either mildly paucisymptomatic or painful, and can lead to a decreased range of motion, secondary screw perforation, and, after many years, osteoarthritis of the glenohumeral joint. The risk of developing osteonecrosis depends mainly on the complexity of the fracture, with Neer type 4 being the most susceptible one, and from the surgical approach. In this study, the rate of AVN was 3.1%. This data is different from the previous review by Sproul et al. [18], where the rate was 10.8%, but it is aligned with the more recent review by Kavuri et al. [19], where it was 4.4%. The probability of reintervention for this type of patient is 35.9%. The decrease of the AVN rate in the reviews over time may be due to different factors, such as an increased propensity in the last years to perform reverse total shoulder arthroplasties or hemi arthroplasties in patients with some severe types (e.g., loss of the medial hinge integrity or loss of the dorsomedial metaphyseal support), and the progressive use of the DS instead of the DP approach [19,40].

Finally, in this study subacromial impingement was the third most frequent complication, with a rate of 1.5%. Sproul et al. [18] reported a rate of 4.8%, while Kavuri et al. [19] of 5.0%, but their results were based on less included studies and not only on PHILOS plate, thus making the current results more reliable and comprehensive. This complication is the consequence of poor intraoperative plate placement or humeral head collapse and causes pain, rotator cuff tendons damage, and osteoarthritis development. The present analysis reports an overall low incidence of this complication for the PHILOS plate, especially when comparing it to the data referred to other plates [18,19,41] or intramedullary nailing [42]. However, patients with this type of complication have a 76% probability of reintervention, which is double the rate of the previous two complications, and consequently, as the third most frequent complication, this data is even more significant.

In addition to the analysis of complications, another important indicator of a successful operation is the reintervention rate, because of the consequences that it implies: increased discomfort for the patient, exposure to another surgical session and the inherent risks, hospitalization, etc., as underlined by Ockert et al. [34], who reported that patients who had a revision had an improvement in shoulder function, but this remained lower than the one of non-reoperated patients. Overall, the reintervention rate in this study was 10.5%, which is aligned to the recent work of Kavuri et al. [19], reporting a rate of 13.8%. Moreover, the current work underlines an increase in the reintervention rate up to 19.0% when considering only patients over 55 years. This increase can also be seen in the study of Luciani et al. [43], which considered only patients over 65 years, and described a complication rate of 34.6%, also confirming previous literature findings [44,45]. In this analysis, the main cause of reintervention was screw cut-out, with a rate of 21.2%. This complication was reported to be the main cause of reintervention also by Sproul et al. [18]

and by other authors [29,35,46]. The second cause of reintervention was AVN, which had a different prevalence among the DP and DS surgical approaches: in the first approach, AVN caused 23.7% of all reinterventions, whereas in the DS approach only 7.7%.

The best surgical approach to address PHFs is an open debate among shoulder surgeons, with the DP being the most common one and the DS being the less used approach [47]. The proximal humerus has rich and fragile vascularity, therefore attention must be paid when performing the DP approach, as an inaccurate and inappropriate surgical exposure during plating increases the risk of osteonecrosis due to a possible injury of the anterior circumflex humeral artery. In contrast, the DS approach reduces soft tissue dissection of the injured region and promotes biological healing at the fracture site, while simultaneously reducing the risk of osteonecrosis. On the other hand, the DS approach implies an increased risk of damage to the axillary nerve, since the insertion and fixation of the plate are in its proximity [48]. Smith et al. [49] reported how this problem can be overcome by using a six-hole PHILOS plate and inserting the screw in the proximal hole and not in the inferior medial oblique hole. Previous literature [50–52], as also reported by the studies of Li et al. [53] and Sohn et al. [47], was not able to find any statistical difference between the DP and DS approaches in terms of complications.

In this systematic review, the overall complication rate in the DP approach was 23.8%, and in the DS approach, it was 17.5%. This result brings a very important addition to the literature, although no statistically significant difference was found, there is a trend difference in the complication rate between the two approaches (p = 0.054). However, besides the different surgical approaches, this result can also be explained by the fact that the DS approach was mainly used for Neer type 2 and 3 fractures, which are easier to treat and carry a lower risk of complications when compared to Neer type 4 fractures [54–56]. In fact, the subanalysis showed that when the DS approach was used in Neer type 4 fractures, it carried a higher risk of complications, probably due to the original trauma itself, as well as the need of these complex fractures for a more dissection of the soft tissues to have better exposure of the fracture site. To this regard, Sohn et al. [47] and Shin et al. [57] recommend a DP approach in Neer type 4 fractures, as a DS approach would cause inadequate fracture alignment, resulting in lower functional outcomes and less patient satisfaction, as largely confirmed by the literature [58–62].

Up to now, there is still a lack of clear guidelines on the use of operative or conservative treatments: operative treatment with the PHILOS plate for young patients is a well-established procedure, whereas for elderly patients with different degrees of osteoporosis and displaced fractures the indications are still not clear, although operative treatment is steadily increasing [63,64]. Given the debated topic, many authors attempted to assess the real benefits of the plate over conservative treatment in the over 60 population. Four recent RCTs compared the two different treatments, showing that no clinical relevance exists to support the surgical approach for any type of Neer fracture [31,65–67], despite the fact that the surgical approach leads to better bone alignment. This result is very important since PHFs are one of the main fractures in the elderly population and consequently the choice of a conservative approach could imply a lower risk of surgically related complications, as underlined by the fact that these RCTs consistently reported a higher complication rate for the locking plate group than for the non-operative treatment group, although in no study a statically significant correlation was found [31,65–67]. These studies reported that subacromial impingement was the main complication in conservatively treated PHFs, but the incidence was lower than the one reported for both locking plate and PHILOS plate treatments. On the other hand, Boons et al. [64], in their systematic review, reported malunion as the main complication in conservative treatment of PHF Neer 4, while the current study found that less than 1% of PHILOS patients can expect this complication. Finally, nowadays neither approach prevails over the other, and both have their pros and cons. Thus, this meta-analysis is of clinical relevance, as it adds important data useful to shed more light on the potential and limitations of the PHILOS approach, which should be considered when managing PHFs patients.

Because of the high rate of complications encountered in PHFs fixation with PHILOS plate, it is important to also assess the clinical outcomes of patients, by using worldwide validated functional scores. In this meta-analysis, the two most used scores in the retrieved paper were CMS and DASH: the first had a mean of 70.8 points and 60% of the included patients achieved a good or better CMS level according to the author's conclusions. This finding is in agreement with the most recent literature, as reported in the studies of Launonen et al. [31] and Olerud et al. [65] which showed an average CMS value similar to that found in this review. Furthermore, in recent years, following the increasing use of locking plates, several authors published studies comparing locking plates for PHFs with conservative strategies, but none of them found better functional outcomes for the surgical treatment, apart from Olerud et al. [65] who, in their RCT, showed that patients treated with locking plate had a faster clinical improvement and better quality of life than those treated conservatively, although without a statistically significant difference and with a 30% risk of additional surgery. This systematic review and meta-analysis builds upon the data of the previous literature on the complications of locking plates further implementing these data, by analyzing a larger number of patients and studies with a specific focus on the PHILOS plate. However, some limitations are still present [18,41]. First of all, the lack of comparative and randomized studies. Second, no study reported homogenous groups of patients <55 years old, thus impairing a comparative analysis between different age ranges. However, the principal strength of this study is the large number of articles and patients included, the clarity of inclusion and exclusion criteria, and the analysis of studies using exclusively PHILOS plates to treat PHFs. Moreover, only studies with a minimum follow-up of 12 months were included, giving the possibility to consider the surgical results stabilized. Thus, overall, this comprehensive review of the complications documented after PHILOS synthesis offers important indications for shoulder and trauma surgeons and suggests the need to further improve the treatment of PHFs to reduce complications and reinterventions.

5. Conclusions

Proximal humerus synthesis with a PHILOS plate has a complication rate of 23.8%, with a reintervention rate of 10.5%, and these values increase up to 29.0% and 19.0%, respectively, in the over-55 population. The most frequent complication in both the overall and the older population groups was screw cut-out, followed by AVN of the humeral head and subacromial impingement. These results of the PHILOS plate will have to be further investigated to better understand both the type of patient and fracture that is more at risk of complications and reintervention and to compare pros and cons with respect to the other solutions to manage patients affected by PHFs.

Author Contributions: Conceptualization, L.M.O. and P.F.; methodology, G.F.; software, J.A.; validation, L.M.O., P.F. and J.A.; formal analysis, G.F.; investigation, L.M.O.; resources, C.C.; data curation, L.M.O.; writing—original draft preparation, L.M.O., P.F. and J.A.; writing—review and editing, G.F., F.M.; visualization, G.F., P.F.; supervision, C.C.; project administration, C.C.; funding acquisition, C.C. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Conflicts of Interest: All authors declare no support from any organization for the submitted work; Christian Candrian has received institutional support outside the present work from Medacta International SA, Johnson & Johnson, Lima Corporate, Zimmer Biomet, and Oped AG.

Appendix A

Explanation of each column question

1. Is the hypothesis/aim/objective of the study clearly described?

2. Are the main outcomes to be measured clearly described in the Introduction or Methods section? If the main outcomes are first mentioned in the Results section, the question should be answered no.

3. Are the characteristics of the patients included in the study clearly described? In cohort studies and trial.s, inclusion and/or exclusion criteria should be given. In case-control studies, a case-definition and the source for controls should be given.

4. Are the interventions of interest clearly described? Treatments and placebo (where relevant) that are to be compared should be clearly described.

5. Are the distributions of principal. confounders in each group of subjects to be compared clearly described? A list of principal. confounders is provided.

6. Are the main findings of the study clearly described? Simple outcome data (including denominators and numerators) should be reported for al.l major findings so that the reader can check the major anal.yses and conclusions. (This question does not cover statistical. tests which are considered below).

7. Does the study provide estimates of the random variability in the data for the main outcomes? In non normal.ly distributed data the inter-quartile range of results should be reported. In normal.ly distributed data the standard error, standard deviation or confidence interval.s should be reported. If the distribution of the data is not described, it must be assumed that the estimates used were appropriate and the question should be answered yes.

8. Have al. I important adverse events that may be a consequence of the intervention been reported? This should be answered yes if the study demonstrates that there was a comprehensive attempt to measure adverse events. (A list of possible adverse events is provided).

9. Have the characteristics of patients lost to follow-up been described? This should be answered yes where there were no losses to follow-up or where losses to follow-up were so smal. I that findings would be unaffected by their inclusion. This should be answered no where a study does not report the number of patients lost to follow-up.

10. Have actual. probability values been reported (e.g. 0.035 rather than <0.05) for the main outcomes except where the probability value is less than 0.001?

11. Were the subjects asked to participate in the study representative of the entire population from which they were recruited? The study must identify the source population for patients and describe how the patients were selected. Patients would be representative if they comprised the entire source population, an unselected sample of consecutive patients, or a random sample. Random sampling is only feasible where a list of al. I members of the relevant population exists. Where a study does not report the proportion of the source population from which the patients are derived, the question should be answered as unable to determine.

12. Were those subjects who were prepared to participate representative of the entire population from which they were recruited? The proportion of those asked who agreed should be stated. Val.idation that the sample was representative would include demonstrating that the distribution of the main confounding factors was the same in the study sample and the source population.

13. Were the staff, places, and facilities where the patients were treated, representative of the treatment the majority of patients receive? For the question to be answered yes the study should demonstrate that the intervention was representative of that in use in the source population. The question should be answered no if, for example, the intervention was undertaken in a special.ist centre unrepresentative of the hospital.s most of the source population would attend.

14. Was an attempt made to blind study subjects to the intervention they have received? For studies where the patients would have no way of knowing which intervention they received, this should be answered yes.

15. Was an attempt made to blind those measuring the main outcomes of the intervention?

16. If any of the results of the study were based on "data dredging", was this made clear? Any anal.yses that had not been planned at the outset of the study should be clearly indicated. If no retrospective unplanned subgroup anal.yses were reported, then answer yes.

17. In trial.s and cohort studies, do the anal.yses adjust for different lengths of follow-up of patients, or in case-control studies, is the time period between the intervention and outcome the same for cases and controls? Where follow-up was the same for al.I study patients the answer should yes. If different lengths of follow-up were adjusted for by, for example, survival. anal.ysis the answer should be yes. Studies where differences in follow-up are ignored should be answered no.

18. Were the statistical. tests used to assess the main outcomes appropriate? The statistical. techniques used must be appropriate to the data. For example nonparametric methods should be used for small sample sizes. Where little statistical analysis has been undertaken but where there is no evidence of bias, the question should be answered yes. If the distribution of the data (normal. or not) is not described it must be assumed that the estimates used were appropriate and the question should be answered yes.

19. Was compliance with the intervention/s reliable? Where there was non compliance with the al.located treatment or where there was contamination of one group, the question should be answered no. For studies where the effect of any misclassification was likely to bias any association to the null, the question should be answered yes.

20. Were the main outcome measures used accurate (val.id and reliable)? For studies where the outcome measures are clearly described, the question should be answered yes. For studies which refer to other work or that demonstrates the outcome measures are accurate, the question should be answered as yes.

21. Were the patients in different intervention groups (trial.s and cohort studies) or were the cases and controls (case-control studies) recruited from the same population? For example, patients for al.l comparison groups should be selected from the same hospital.. The question should be answered unable to determine for cohort and casecontrol studies where there is no information concerning the source of patients included in the study.

22. Were study subjects in different intervention groups (trial.s and cohort studies) or were the cases and controls (case-control studies) recruited over the same period of time? For a study which does not specify the time period over which patients were recruited, the question should be answered as unable to determine.

23. Were study subjects randomised to intervention groups? Studies which state that subjects were randomized should be answered yes except where method of randomisation would not ensure random al.location. For example al.ternate al.location would score no because it is predictable.

24. Was the randomised intervention assignment conceal.ed from both patients and heal.th care staff until recruitment was complete and irrevocable? Al.I non-randomised studies should be answered no. If assignment was conceal.ed from patients but not from staff, it should be answered no.

25. Was there adequate adjustment for confounding in the anal.yses from which the main findings were drawn? This question should be answered no for trial.s if: the main conclusions of the study were based on anal.yses of treatment rather than intention to treat; the distribution of known confounders in the different treatment groups was not described; or the distribution of known confounders differed between the treatment groups but was not taken into account in the anal.yses. In non-randomized studies if the effect of the main confounders was not investigated or confounding was demonstrated but no adjustment was made in the final. anal.yses the question should be answered as no.

26. Were losses of patients to follow-up taken into account? If the numbers of patients lost to follow-up are not reported, the question should be answered as unable to determine. If the proportion lost to follow-up was too smal. I to affect the main findings, the question should be answered yes.

27. Did the study have sufficient power to detect a clinical.ly important effect where the probability val.ue for a difference being due to chance is less than 5%? Sample sizes have been cal.culated to detect a difference of x% and y%.

References

- Court-Brown, C.M.; Garg, A.; McQueen, M.M. The translated two-part fracture of the proximal humerus. Epidemiology and outcome in the older patient. J. Bone Jt. Surg. Br. Vol. 2001, 83, 799–804. [CrossRef]
- 2. Baron, J.A.; Barrett, J.A.; Karagas, M.R. The epidemiology of peripheral fractures. Bone 1996, 18 (Suppl. 3), 209s–213s. [CrossRef]
- 3. Launonen, A.P.; Lepola, V.; Saranko, A.; Flinkkilä, T.; Laitinen, M.; Mattila, V.M. Epidemiology of proximal humerus fractures. *Arch. Osteoporos.* **2015**, *10*, 209. [CrossRef] [PubMed]
- 4. Carofino, B.C.; Leopold, S.S. Classifications in brief: The Neer classification for proximal humerus fractures. *Clin. Orthop. Relat. Res.* **2013**, 471, 39–43. [CrossRef] [PubMed]
- Gumina, S.; Candela, V.; Giannicola, G.; Orsina, L.; Passaretti, D.; Villani, C. Complex humeral head fractures treated with blocked threaded wires: Maintenance of the reduction and clinical results with two different fixation constructs. *J. Shoulder Elb. Surg.* 2019, 28, 36–41. [CrossRef] [PubMed]
- 6. Schumaier, A.; Grawe, B. Proximal Humerus Fractures: Evaluation and Management in the Elderly Patient. *Geriatr. Orthop. Surg. Rehabil.* **2018**, *9*, 2151458517750516. [CrossRef] [PubMed]
- Egol, K.A.; Sugi, M.T.; Ong, C.C.; Montero, N.; Davidovitch, R.; Zuckerman, J.D. Fracture site augmentation with calcium phosphate cement reduces screw penetration after open reduction-internal fixation of proximal humeral fractures. *J. Shoulder Elb. Surg.* 2012, *21*, 741–748. [CrossRef]

- Chalmers, P.N.; Slikker, W., 3rd; Mall, N.A.; Gupta, A.K.; Rahman, Z.; Enriquez, D.; Nicholson, G.P. Reverse total shoulder arthroplasty for acute proximal humeral fracture: Comparison to open reduction-internal fixation and hemiarthroplasty. *J. Shoulder Elb. Surg.* 2014, 23, 197–204. [CrossRef]
- 9. Solberg, B.D.; Moon, C.N.; Franco, D.P.; Paiement, G.D. Locked plating of 3- and 4-part proximal humerus fractures in older patients: The effect of initial fracture pattern on outcome. *J. Orthop. Trauma* **2009**, *23*, 113–119. [CrossRef]
- 10. Haidukewych, G.J. Innovations in locking plate technology. J. Am. Acad. Orthop. Surg. 2004, 12, 205–212. [CrossRef]
- 11. Lichtman, D.M.; Bindra, R.R.; Boyer, M.I.; Putnam, M.D.; Ring, D.; Slutsky, D.J.; Taras, J.S.; Watters, W.C., 3rd; Goldberg, M.J.; Keith, M.; et al. Treatment of distal radius fractures. *J. Am. Acad. Orthop. Surg.* **2010**, *18*, 180–189. [CrossRef] [PubMed]
- 12. Vallier, H.A. Treatment of proximal humerus fractures. J. Orthop. Trauma 2007, 21, 469–476. [CrossRef] [PubMed]
- 13. Downs, S.H.; Black, N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. *J. Epidemiol. Community Health* **1998**, *52*, 377–384. [CrossRef] [PubMed]
- 14. Newcombe, R.G. Two-sided confidence intervals for the single proportion: Comparison of seven methods. *Stat. Med.* **1998**, 17, 857–872. [CrossRef]
- 15. Neer, C.S. 2nd. Displaced proximal humeral fractures. I. Classification and evaluation. J. Bone Jt. Surg. Am. Vol. 1970, 52, 1077–1089. [CrossRef]
- 16. Constant, C.R.; Gerber, C.; Emery, R.J.; Søjbjerg, J.O.; Gohlke, F.; Boileau, P. A review of the Constant score: Modifications and guidelines for its use. *J. Shoulder Elb. Surg.* **2008**, *17*, 355–361. [CrossRef]
- Hudak, P.L.; Amadio, P.C.; Bombardier, C. Development of an upper extremity outcome measure: The DASH (disabilities of the arm, shoulder and hand) [corrected]. The Upper Extremity Collaborative Group (UECG). Am. J. Ind. Med. 1996, 29, 602–608. [CrossRef]
- 18. Sproul, R.C.; Iyengar, J.J.; Devcic, Z.; Feeley, B.T. A systematic review of locking plate fixation of proximal humerus fractures. *Injury* **2011**, *42*, 408–413. [CrossRef]
- Kavuri, V.; Bowden, B.; Kumar, N.; Cerynik, D. Complications Associated with Locking Plate of Proximal Humerus Fractures. Indian J. Orthop. 2018, 52, 108–116.
- Faraj, D.; Kooistra, B.W.; Stappen, W.A.H.V.; Werre, A.J. Results of 131 consecutive operated patients with a displaced proximal humerus fracture: An analysis with more than two years follow-up. *Eur. J. Orthop. Surg. Traumatol. Orthop. Traumatol.* 2011, 21, 7–12. [CrossRef]
- Sun, J.-C.; Li, Y.-L.; Ning, G.-Z.; Wu, Q.; Feng, S.-Q. Treatment of three- and four-part proximal humeral fractures with locking proximal humerus plate. *Eur. J. Orthop. Surg. Traumatol. Orthop. Traumatol.* 2013, 23, 699–704. [CrossRef] [PubMed]
- Südkamp, N.; Bayer, J.; Hepp, P.; Voigt, C.; Oestern, H.; Kääb, M.; Luo, C.; Plecko, M.; Wendt, K.; Köstler, W.; et al. Open reduction and internal fixation of proximal humeral fractures with use of the locking proximal humerus plate. Results of a prospective, multicenter, observational study. J. Bone Jt. Surg. Am. Vol. 2009, 91, 1320–1328. [CrossRef]
- 23. Spross, C.; Platz, A.; Rufibach, K.; Lattmann, T.; Forberger, J.; Dietrich, M. The PHILOS plate for proximal humeral fractures—risk factors for complications at one year. *J. Trauma Acute Care Surg.* **2012**, *72*, 783–792. [CrossRef] [PubMed]
- Hirschmann, M.T.; Quarz, V.; Audigé, L.; Ludin, D.; Messmer, P.; Regazzoni, P.; Gross, T. Internal fixation of unstable proximal humerus fractures with an anatomically preshaped interlocking plate: A clinical and radiologic evaluation. *J. Trauma* 2007, 63, 1314–1323. [CrossRef]
- Barlow, J.D.; Logli, A.L.; Steinmann, S.P.; Sems, S.A.; Cross, W.W.; Yuan, B.J.; Torchia, M.E.; Sanchez-Sotelo, J. Locking plate fixation of proximal humerus fractures in patients older than 60 years continues to be associated with a high complication rate. *J. Shoulder Elb. Surg.* 2020, 29, 1689–1694. [CrossRef] [PubMed]
- Hardeman, F.; Bollars, P.; Donnelly, M.; Bellemans, J.; Nijs, S. Predictive factors for functional outcome and failure in angular stable osteosynthesis of the proximal humerus. *Injury* 2012, 43, 153–158. [CrossRef] [PubMed]
- Lee, S.H.; Dargent-Molina, P.; Breart, G. Risk factors for fractures of the proximal humerus: Results from the EPIDOS prospective study. J. Bone Miner. Res. 2002, 17, 817–825. [CrossRef] [PubMed]
- Cha, H.; Park, K.-B.; Oh, S.; Jeong, J. Treatment of comminuted proximal humeral fractures using locking plate with strut allograft. J. Shoulder Elb. Surg. 2017, 26, 781–785. [CrossRef]
- Fraser, A.N.; Bjørdal, J.; Wagle, T.M.; Karlberg, A.C.; Lien, O.A.; Eilertsen, L.; Mader, K.; Apold, H.; Larsen, L.B.; Madsen, J.E.; et al. Reverse Shoulder Arthroplasty Is Superior to Plate Fixation at 2 Years for Displaced Proximal Humeral Fractures in the Elderly: A Multicenter Randomized Controlled Trial. *J. Bone Jt. Surg. Am. Vol.* 2020, 102, 477–485. [CrossRef]
- Beeres, F.J.P.; Hallensleben, N.D.L.; Rhemrev, S.J.; Goslings, J.C.; Oehme, F.; Meylaerts, S.A.G.; Babst, R.; Schep, N.W.L. Plate fixation of the proximal humerus: An international multicentre comparative study of postoperative complications. *Arch. Orthop. Trauma Surg.* 2017, 137, 1685–1692. [CrossRef]
- Launonen, A.P.; Sumrein, B.O.; Reito, A.; Lepola, V.; Paloneva, J.; Jonsson, K.B.; Wolf, O.; Ström, P.; Berg, H.E.; Felländer-Tsai, L.; et al. Operative versus non-operative treatment for 2-part proximal humerus fracture: A multicenter randomized controlled trial. *PLoS Med.* 2019, 16, e1002855. [CrossRef] [PubMed]
- 32. Borer, J.; Schwarz, J.; Potthast, S.; Jakob, M.; Lenzlinger, P.; Zingg, U.; Babians, A. Mid-term results of minimally invasive deltoidsplit versus standard open deltopectoral approach for PHILOS[™] (proximal humeral internal locking system) osteosynthesis in proximal humeral fractures. *Eur. J. Trauma Emerg. Surg.* **2020**, *46*, 825–834. [CrossRef] [PubMed]

- 33. Shi, H.-F.; Xiong, J.; Chen, Y.-X.; Wang, J.-F.; Wang, S.-F.; Chen, Z.-J.; Qiu, Y. Management of proximal humeral fractures in elderly patients with uni- or polyaxial locking osteosynthesis system. *Arch. Orthop. Trauma Surg.* **2011**, *131*, 541–547. [CrossRef] [PubMed]
- Plath, J.E.; Kerschbaum, C.; Seebauer, T.; Holz, R.; Henderson, D.J.H.; Förch, S.; Mayr, E. Locking nail versus locking plate for proximal humeral fracture fixation in an elderly population: A prospective randomised controlled trial. *BMC Musculoskelet*. *Disord.* 2019, 20, 20. [CrossRef] [PubMed]
- Matejčić, A.; Vidović, D.; Ivica, M.; Đurđević, D.; Tomljenović, M.; Bekavac-Bešlin, M.; Mijić, A.; Punda, M.; Bakota, B.; Misir, Z. Internal fixation with locking plate of 3- and 4-part proximal humeral fractures in elderly patients: Complications and functional outcome. *Acta Clin. Croat.* 2013, 52, 17–22.
- Cai, M.; Tao, K.; Yang, C.; Li, S. Internal fixation versus shoulder hemiarthroplasty for displaced 4-part proximal humeral fractures in elderly patients. *Orthopedics* 2012, 35, e1340–e1346. [CrossRef]
- Hengg, C.; Nijs, S.; Klopfer, T.; Jaeger, M.; Platz, A.; Pohlemann, T.; Babst, R.; Franke, J.; Kralinger, F. Cement augmentation of the proximal humerus internal locking system in elderly patients: A multicenter randomized controlled trial. *Arch. Orthop. Trauma Surg.* 2019, 139, 927–942. [CrossRef]
- Voigt, C.; Geisler, A.; Hepp, P.; Schulz, A.P.; Lill, H. Are polyaxially locked screws advantageous in the plate osteosynthesis of proximal humeral fractures in the elderly? A prospective randomized clinical observational study. *J. Orthop. Trauma* 2011, 25, 596–602. [CrossRef]
- 40. Hertel, R.; Hempfing, A.; Stiehler, M.; Leunig, M. Predictors of humeral head ischemia after intracapsular fracture of the proximal humerus. *J. Shoulder Elb. Surg.* **2004**, *13*, 427–433. [CrossRef]
- 41. Thanasas, C.; Kontakis, G.; Angoules, A.; Limb, D.; Giannoudis, P. Treatment of proximal humerus fractures with locking plates: A systematic review. *J. Shoulder Elb. Surg.* **2009**, *18*, 837–844. [CrossRef] [PubMed]
- Gracitelli, M.E.; Malavolta, E.A.; Assunção, J.H.; Kojima, K.E.; dos Reis, P.R.; Silva, J.S.; Ferreira, A.A.N.; Hernandez, A.J. Locking intramedullary nails compared with locking plates for two- and three-part proximal humeral surgical neck fractures: A randomized controlled trial. *J. Shoulder Elb. Surg.* 2016, 25, 695–703. [CrossRef] [PubMed]
- 43. Luciani, P.; Procaccini, R.; Rotini, M.; Pettinari, F.; Gigante, A. Angular stable plate versus reverse shoulder arthroplasty for proximal humeral fractures in elderly patient. *Musculoskelet. Surg.* **2020**, *104*, 1–6. [CrossRef] [PubMed]
- 44. Boesmueller, S.; Wech, M.; Gregori, M.; Domaszewski, F.; Bukaty, A.; Fialka, C.; Albrecht, C. Risk factors for humeral head necrosis and non-union after plating in proximal humeral fractures. *Injury* **2016**, *47*, 350–355. [CrossRef]
- 45. Du, S.; Ye, J.; Chen, H.; Li, X.; Lin, Q. Interventions for Treating 3- or 4-part proximal humeral fractures in elderly patient: A network meta-analysis of randomized controlled trials. *Int. J. Surg.* **2017**, *48*, 240–246. [CrossRef]
- Zeng, L.-Q.; Zeng, L.-L.; Jiang, Y.-W.; Wei, H.-F.; Zhang, W.; Chen, Y.-F. Influence of Medial Support Screws on the Maintenance of Fracture Reduction after Locked Plating of Proximal Humerus Fractures. *Chin. Med. J.* 2018, 131, 1827–1833. [CrossRef]
- 47. Sohn, H.-S.; Jeon, Y.S.; Lee, J.; Shin, S.-J. Clinical comparison between open plating and minimally invasive plate osteosynthesis for displaced proximal humeral fractures: A prospective randomized controlled trial. *Injury* **2017**, *48*, 1175–1182. [CrossRef]
- Acklin, Y.P.; Jenni, R.; Walliser, M.; Sommer, C. Minimal Invasive PHILOS(®)-Plate Osteosynthesis in Proximal Humeral Fractures. *Eur. J. Trauma Emerg. Surg.* 2009, 35, 35–39. [CrossRef]
- 49. Smith, J.; Berry, G.; Laflamme, Y.; Blain-Pare, E.; Reindl, R.; Harvey, E. Percutaneous insertion of a proximal humeral locking plate: An anatomic study. *Injury* 2007, *38*, 206–211. [CrossRef]
- 50. Acklin, Y.P.; Stoffel, K.; Sommer, C. A prospective analysis of the functional and radiological outcomes of minimally invasive plating in proximal humerus fractures. *Injury* **2013**, *44*, 456–460. [CrossRef]
- 51. Ruchholtz, S.; Hauk, C.; Lewan, U.; Franz, D.; Kühne, C.; Zettl, R. Minimally invasive polyaxial locking plate fixation of proximal humeral fractures: A prospective study. *J. Trauma* 2011, *71*, 1737–1744. [CrossRef] [PubMed]
- 52. Hirschmann, M.T.; Fallegger, B.; Amsler, F.; Regazzoni, P.; Gross, T. Clinical longer-term results after internal fixation of proximal humerus fractures with a locking compression plate (PHILOS). *J. Orthop. Trauma* **2011**, *25*, 286–293. [CrossRef] [PubMed]
- Li, F.; Liu, X.; Wang, F.; Gu, Z.; Tao, Q.; Yao, C.; Luo, X.; Nie, T. Comparison between minimally invasive plate osteosynthesis and open reduction-internal fixation for proximal humeral fractures: A meta-analysis based on 1050 individuals. *BMC Musculoskelet*. *Disord.* 2019, 20, 550. [CrossRef] [PubMed]
- 54. Rouleau, D.-M.; Laflamme, G.-Y.; Berry, G.K.; Harvey, E.J.; Delisle, J.; Girard, J. Retraction notice to Proximal humerus fractures treated by percutaneous locking plate internal fixation. [OTSR 95/1 (2009) 56–62]. *Orthop. Traumatol. Surg. Res.* 2010, *96*, 490–491. [CrossRef] [PubMed]
- 55. Gavaskar, A.S.; Muthukumar, S.; Chowdary, N. Biological osteosynthesis of complex proximal humerus fractures: Surgical technique and results from a prospective single center trial. *Arch. Orthop. Trauma Surg.* **2010**, *130*, 667–672. [CrossRef]
- 56. Laflamme, G.Y.; Rouleau, D.M.; Berry, G.K.; Beaumont, P.H.; Reindl, R.; Harvey, E.J. Percutaneous humeral plating of fractures of the proximal humerus: Results of a prospective multicenter clinical trial. *J. Orthop. Trauma* **2008**, 22, 153–158. [CrossRef]
- 57. Sohn, H.-S.; Shin, S.-J. Minimally invasive plate osteosynthesis for proximal humeral fractures: Clinical and radiologic outcomes according to fracture type. *J. Shoulder Elb. Surg.* **2014**, *23*, 1334–1340. [CrossRef]
- 58. Björkenheim, J.-M.; Pajarinen, J.; Savolainen, V. Internal fixation of proximal humeral fractures with a locking compression plate: A retrospective evaluation of 72 patients followed for a minimum of 1 year. *Acta Orthop. Scand.* **2004**, *75*, 741–745. [CrossRef]

- 59. Koukakis, A.; Apostoloum, C.D.; Taneja, T.; Korres, D.S.; Amini, A. Fixation of proximal humerus fractures using the PHILOS plate: Early experience. *Clin. Orthop. Relat. Res.* **2006**, 442, 115–120. [CrossRef]
- 60. Lill, H.; Hepp, P.; Rose, T.; König, K.; Josten, C. The angle stable locking-proximal-humerus-plate (LPHP) for proximal humeral fractures using a small anterior-lateral-deltoid-splitting-approach—technique and first results. *Zent. Fur Chir.* 2004, 129, 43–48.
- Lin, T.; Xiao, B.; Ma, X.; Fu, D.; Yang, S. Minimally invasive plate osteosynthesis with a locking compression plate is superior to open reduction and internal fixation in the management of the proximal humerus fractures. *BMC Musculoskelet. Disord.* 2014, 15, 206. [CrossRef] [PubMed]
- 62. Wu, X.; Liu, K.; Liu, P.-C.; Liu, R. Advantage of minimally invasive lateral approach relative to conventional deltopectoral approach for treatment of proximal humerus fractures. *Med. Sci. Monit.* **2015**, *21*, 496–504. [CrossRef] [PubMed]
- 63. Lanting, B.; MacDermid, J.; Drosdowech, D.; Faber, K.J. Proximal humeral fractures: A systematic review of treatment modalities. *J. Shoulder Elb. Surg.* **2008**, *17*, 42–54. [CrossRef] [PubMed]
- 64. Boons, H.W.; Goosen, J.H.; van Grinsven, S.; van Susante, J.L.; van Loon, C.J. Hemiarthroplasty for humeral four-part fractures for patients 65 years and older: A randomized controlled trial. *Clin. Orthop. Relat. Res.* **2012**, 470, 3483–3491. [CrossRef] [PubMed]
- Olerud, P.; Ahrengart, L.; Ponzer, S.; Saving, J.; Tidermark, J. Internal fixation versus nonoperative treatment of displaced 3-part proximal humeral fractures in elderly patients: A randomized controlled trial. *J. Shoulder Elb. Surg.* 2011, 20, 747–755. [CrossRef] [PubMed]
- 66. Fjalestad, T.; Hole, M.; Hovden, I.A.; Blücher, J.; Strømsøe, K. Surgical treatment with an angular stable plate for complex displaced proximal humeral fractures in elderly patients: A randomized controlled trial. *J. Orthop. Trauma* **2012**, *26*, 98–106. [CrossRef]
- 67. Rangan, A.; Handoll, H.; Brealey, S.; Jefferson, L.; Keding, A.; Martin, B.C.; Goodchild, L.; Chuang, L.-H.; Hewitt, C.; Torgerson, D.; et al. Surgical vs nonsurgical treatment of adults with displaced fractures of the proximal humerus: The PROFHER randomized clinical trial. *JAMA* **2015**, *313*, 1037–1047. [CrossRef]